Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Ethan Lazarus and our team of obesity medicine specialists provide the kind of comprehensive, physician-supervised care thats hard to find anywhere else in the Denver metro area
Outcomes in cardiometabolic risk GLP1R expression has been detected at low levels in human atria and ventricles, both in cardiomyocytes and endothelial cells, though its precise localization remains unclear due to limitations in antibody specificity and differences at species level [93]
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
WeightWatchers Clinic prescribes a wide range of GLP-1 medications, more than almost any other weight-loss clinic
